Skip to main content
STELLA PHARMA CORPORATION logo

STELLA PHARMA CORPORATION — Investor Relations & Filings

Ticker · 4888 ISIN · JP3399680002 T Manufacturing
Open in API
Filings indexed 50 across all filing types
Latest filing 2026-06-05 Share Issue/Capital Cha…
Country JP Japan
Listing T 4888

About STELLA PHARMA CORPORATION

https://stella-pharma.co.jp/

Stella Pharma Corporation is a pharmaceutical company focused on the research and development of therapeutic drugs. The company specializes in boron compounds for Boron Neutron Capture Therapy (BNCT), a form of targeted radiation therapy for cancer. As a pioneer in the field, Stella Pharma developed the boron-based drug used in the first approved BNCT treatment for unresectable head and neck cancers. Its development pipeline is focused on expanding the application of BNCT to other difficult-to-treat malignancies, with clinical trials investigating its use for conditions such as cutaneous angiosarcoma.

Recent filings

Filing Released Lang Actions
株式及び新株予約権発行プログラム設定契約に基づく第２回第三者割当による新株式及び新株予約権の発行に関するお知らせ
Share Issue/Capital Change Classification · 90% confidence The document is a formal corporate announcement detailing the terms and conditions of a third-party allotment issuance of new ordinary shares and share warrants, including number of shares, issue price, allottee, funds to be raised, purposes and schedule. This clearly constitutes a notification of new share issuance under capital‐raising, matching the 'Share Issue/Capital Change' category.
2026-06-05 Japanese
発行登録追補書類（株券､社債券等）
Share Issue/Capital Change Classification · 92% confidence The document is a Japanese issuance registration supplementary disclosure (“発行登録追補書類”) filed with the Kinki Local Finance Bureau that provides the full terms, conditions, amounts, and use of proceeds for a new issuance of share subscription rights (新株予約権証券). It is not merely an announcement that a report has been published, nor an interim or annual report; it is a detailed disclosure of a share issuance under the Financial Instruments and Exchange Act. Accordingly, it fits the “Share Issue/Capital Change” category (SHA).
2026-06-05 Japanese
発行登録追補書類（株券､社債券等）
Share Issue/Capital Change Classification · 90% confidence The document is an official Japanese issuance registration supplement (“発行登録追補書類”) detailing a third-party allotment of new shares (1,000,000 ordinary shares), offering conditions, use of proceeds, and related capital change information. This is a statutory filing about a share issue, not a general report publication or earnings release. It falls squarely under Share Issue/Capital Change.
2026-06-05 Japanese
2026年３月期　決算説明会資料
Investor Presentation Classification · 95% confidence The document is titled “2026年3月期 決算説明会資料” dated May 26, 2026 (fiscal year ending March 2026 results briefing materials) from Stella Pharma. It contains corporate overview, full‐year results, forecasts, financial strategy and growth strategy in slide format. This is a detailed presentation deck used for an investor/analyst results briefing rather than the statutory Annual Report or a press‐style earnings release. Therefore it fits the “Investor Presentation” (IP) category.
2026-05-26 Japanese
役員人事に関するお知らせ
Board/Management Information Classification · 91% confidence The document is a corporate announcement detailing proposed changes to the company’s board of directors, including candidate appointments, reappointments, and retirements to be approved at the upcoming shareholders’ meeting. This clearly falls under board/management information.
2026-05-20 Japanese
再発膠芽腫を対象とした国内第III相臨床試験の治験開始に関するお知らせ
Regulatory Filings Classification · 85% confidence The document is a corporate announcement by a listed Japanese company (ステラファーマ株式会社) that informs investors and stakeholders of the start of a domestic Phase III clinical trial for recurrent glioblastoma under BNCT, outlines the trial details, funding use sourced from a previously disclosed share issuance program, and provides the company outlook. There are no financial statements, management changes, dividend notices, or regulatory form filings beyond a routine disclosure. It serves as a regulatory announcement of a clinical trial start rather than an earnings release, financing update, or management report, so it falls under General Regulatory Filings.
2026-05-18 Japanese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.